CLEVELAND, May 12, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will participate in an open forum discussion at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 4:35 pm Eastern. Sotera Health management will also participate in one-on-one meetings with investors during the conference.
Investors and the general public are invited to listen to the live webcast of Mr. Petras’ discussion by accessing the link on the Sotera Health website under the Investor Relations section: https://investors.soterahealth.com/events-and-presentations. A replay will also be made available.
About Sotera Health:
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
INVESTOR RELATIONS CONTACTS: | ||
Jason Peterson Vice President & Treasurer Sotera Health Company This email address is being protected from spambots. You need JavaScript enabled to view it. | Sally J. Curley, IRC IR Advisory Solutions This email address is being protected from spambots. You need JavaScript enabled to view it. | |
MEDIA CONTACT: | ||
Kristin Gibbs Chief Marketing Officer Sotera Health Company This email address is being protected from spambots. You need JavaScript enabled to view it. | ||
Last Trade: | US$11.38 |
Daily Change: | -0.23 -1.98 |
Daily Volume: | 980,028 |
Market Cap: | US$3.230B |
May 01, 2025 March 04, 2025 February 27, 2025 January 14, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load